Largest health care pharmaceutical companies by revenue
Everything the company sold in its latest fiscal year, before any cost is taken off.
Johnson & Johnson leads the 52 health care pharmaceutical companies ranked by revenue, at NOK 918.3B, ahead of Eli Lilly (NOK 635.4B) and Merck & Co (NOK 633.8B). Figures as of 20 Nov 2026, 11:15 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 52
- First
- Johnson & JohnsonNOK 918.3B
- Median
- NOK 31.2B
- Combined market value
- NOK 48.38T
- Countries
- 10
- Not ranked
- 9no revenue on file
Market values as of .
All countries▾
Health Care▾
Pharmaceuticals▾
| # | Company | Revenue ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Johnson & JohnsonJNJ · Health Care | NOK 918.3B | NOK 6.27T | NOK 2,604.41 | 2.04% down | 34% up | ||
| 2 | Eli LillyLLY · Health Care | NOK 635.4B | NOK 11.73T | NOK 13,172.39 | 2.29% down | 33% up | ||
| 3 | Merck & CoMRK · Health Care | NOK 633.8B | NOK 3.19T | NOK 1,294.80 | 3.61% down | 45% up | ||
| 4 | PfizerPFE · Health Care | NOK 610.1B | NOK 1.53T | NOK 268.49 | 1.85% down | 15% up | ||
| 5 | AbbVieABBV · Health Care | NOK 596.3B | NOK 4.89T | NOK 2,764.30 | 0.86% down | 25% up | ||
| 6 | AstraZenecaAZN · Health Care | NOK 572.7B | NOK 2.65T | NOK 1,710.11 | 1.87% down | 1% up | ||
| 7 | NovartisNVS · Health Care | NOK 531.6B | NOK 2.78T | NOK 1,474.28 | 2.57% down | 25% up | ||
| 8 | SanofiSNY · Health Care | NOK 471.9B | NOK 1.08T | NOK 449.05 | 2.25% down | 4% down | ||
| 9 | Bristol-Myers SquibbBMY · Health Care | NOK 469.9B | NOK 1.16T | NOK 568.77 | 2.05% down | 30% up | ||
| 10 | Novo NordiskNVO · Health Care | NOK 447.1B | NOK 1.67T | NOK 378.95 | 1.42% down | 17% down | ||
| 11 | Abbott LaboratoriesABT · Health Care | NOK 432.2B | NOK 1.75T | NOK 1,012.65 | 0.58% down | 16% down | ||
| 12 | GSKGSK · Health Care | NOK 422.7B | NOK 934.5B | NOK 466.21 | 1.56% down | 5% up | ||
| 13 | Takeda PharmaceuticalTAK · Health Care | NOK 275.1B | NOK 666.9B | NOK 208.73 | 0.66% up | 51% up | ||
| 14 | Teva Pharmaceutical IndustriesTEVA · Health Care | NOK 168.3B | NOK 438.4B | NOK 375.74 | 8.74% down | 74% up | ||
| 15 | Regeneron PharmaceuticalsREGN · Health Care | NOK 139.8B | NOK 931.2B | NOK 9,001.86 | 2.35% down | 28% up | ||
| 16 | ViatrisVTRS · Health Care | NOK 139.4B | NOK 222.2B | NOK 193.81 | 1.97% down | 99% up | ||
| 17 | Vertex PharmaceuticalsVRTX · Health Care | NOK 117B | NOK 1.29T | NOK 5,076.04 | 2.94% down | 27% up | ||
| 18 | ZoetisZTS · Health Care | NOK 92.3B | NOK 320B | NOK 787.64 | 5.59% down | 26% down | ||
| 19 | GrifolsGRFS · Health Care | NOK 81.4B | NOK 54.4B | NOK 79.94 | 3.19% down | 0% up | ||
| 20 | BeOne MedicinesONC · Health Care | NOK 52.1B | NOK 445.1B | NOK 3,896.77 | 0.97% down | 16% up | ||
| 21 | Elanco Animal HealthELAN · Health Care | NOK 46B | NOK 128.1B | NOK 256.31 | 1.54% down | 26% up | ||
| 22 | Jazz PharmaceuticalsJAZZ · Health Care | NOK 41.6B | NOK 148B | NOK 2,305.21 | 4.57% down | 41% up | ||
| 23 | GenmabGMAB · Health Care | NOK 36.3B | NOK 308.7B | NOK 500.62 | 0.75% up | 70% up | ||
| 24 | Alnylam PharmaceuticalsALNY · Health Care | NOK 36.2B | NOK 193B | NOK 1,441.13 | 1.06% down | 66% down | ||
| 25 | Dr. Reddy's LaboratoriesRDY · Health Care | NOK 34.8B | NOK 120.5B | NOK 144.58 | 1.00% down | 8% up | ||
| 26 | BioMarin PharmaceuticalBMRN · Health Care | NOK 31.4B | NOK 116B | NOK 598.80 | 0.02% down | 17% up | ||
| 27 | United TherapeuticsUTHR · Health Care | NOK 31B | NOK 232.1B | NOK 5,450.80 | 3.16% down | 22% up | ||
| 28 | Amneal PharmaceuticalsAMRX · Health Care | NOK 29.4B | NOK 72.7B | NOK 208.54 | 2.24% down | 90% up | ||
| 29 | Royalty PharmaRPRX · Health Care | NOK 23.2B | NOK 379.6B | NOK 660.22 | 1.38% down | 79% up | ||
| 30 | PTC TherapeuticsPTCT · Health Care | NOK 16.9B | NOK 47.5B | NOK 568.62 | 3.16% down | 21% down | ||
| 31 | AlkermesALKS · Health Care | NOK 14.4B | NOK 75.7B | NOK 450.22 | 1.43% down | 66% up | ||
| 32 | Legend BiotechLEGN · Health Care | NOK 10B | NOK 30.4B | NOK 156.96 | 0.92% down | 41% down | ||
| 33 | Madrigal PharmaceuticalsMDGL · Health Care | NOK 9.3B | NOK 89.8B | NOK 3,867.91 | 0.34% down | 27% down | ||
| 34 | Ionis PharmaceuticalsIONS · Health Care | NOK 9.2B | NOK 44.2B | NOK 265.37 | 0.62% down | 63% down | ||
| 35 | Arrowhead PharmaceuticalsARWR · Health Care | NOK 8.1B | NOK 60.2B | NOK 425.55 | 1.25% up | 13% up | ||
| 36 | Ascendis PharmaASND · Health Care | NOK 7.8B | NOK 163.7B | NOK 2,495.42 | 5.32% down | 29% up | ||
| 37 | Corcept TherapeuticsCORT · Health Care | NOK 7.4B | NOK 69.3B | NOK 633.51 | 4.15% down | 10% down | ||
| 38 | Kiniksa Pharmaceuticals InternationalKNSA · Health Care | NOK 6.6B | NOK 71.6B | NOK 911.90 | 1.59% down | 129% up | ||
| 39 | Axsome TherapeuticsAXSM · Health Care | NOK 6.2B | NOK 69.6B | NOK 1,322.78 | 1.25% up | 6% down | ||
| 40 | TG TherapeuticsTGTX · Health Care | NOK 6B | NOK 95.6B | NOK 632.53 | 1.88% down | 117% up | ||
| 41 | InsmedINSM · Health Care | NOK 5.9B | NOK 309B | NOK 1,408.38 | 20.58% up | 40% down | ||
| 42 | Mirum PharmaceuticalsMIRM · Health Care | NOK 5.1B | NOK 60.8B | NOK 931.15 | 3.27% up | 34% up | ||
| 43 | BridgeBio PharmaBBIO · Health Care | NOK 4.9B | NOK 148.5B | NOK 762.20 | 0.22% up | 21% up | ||
| 44 | Travere TherapeuticsTVTX · Health Care | NOK 4.8B | NOK 45.2B | NOK 470.89 | 3.86% down | 45% up | ||
| 45 | Ligand PharmaceuticalsLGND · Health Care | NOK 2.6B | NOK 56B | NOK 2,797.45 | 3.94% down | 50% up | ||
| 46 | Rhythm PharmaceuticalsRYTM · Health Care | NOK 1.8B | NOK 78.9B | NOK 1,138.71 | 1.88% down | 18% up | ||
| 47 | CytokineticsCYTK · Health Care | NOK 858.3M | NOK 69.9B | NOK 501.70 | 0.27% up | 19% down | ||
| 48 | Protagonist TherapeuticsPTGX · Health Care | NOK 448.6M | NOK 78.9B | NOK 1,209.10 | 2.47% down | 51% up | ||
| 49 | Roivant SciencesROIV · Health Care | NOK 80.5M | NOK 275.2B | NOK 379.83 | 0.59% up | 91% up | ||
| 50 | Dianthus TherapeuticsDNTH · Health Care | NOK 19.8M | NOK 46.6B | NOK 827.03 | 1.01% up | 108% up | ||
| 51 | Spyre TherapeuticsSYRE · Health Care | NOK 0 | NOK 90.4B | NOK 951.82 | 3.77% down | 332% up | ||
| 52 | Praxis Precision MedicinesPRAX · Health Care | NOK 0 | NOK 84.7B | NOK 3,031.04 | 1.87% up | 86% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Revenue is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 9.7492 NOK). 9 companies have no revenue on file and are not ranked here.
Questions and answers
Which health care pharmaceutical companies rank first by revenue?
Johnson & Johnson (NOK 918.3B), Eli Lilly (NOK 635.4B) and Merck & Co (NOK 633.8B) are the top three of the 52 health care pharmaceutical companies ranked by revenue as of 20 Nov 2026, 11:15 UTC.
How many health care pharmaceutical companies are in this ranking?
52 are ranked by revenue. 9 more have no revenue on file and are left out rather than ranked at zero.
What are these health care pharmaceutical companies worth together?
The 52 health care pharmaceutical companies ranked by revenue have a combined market value of NOK 48.38T as of 20 Nov 2026, 11:15 UTC.
What does ranking by revenue measure?
Everything the company sold in its latest fiscal year, before any cost is taken off.
Learn how this ranking works
All markets guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
- How companies are sorted into sectors and industries
Companies are sorted into sectors and industries by classification systems. The index providers MSCI and S&P Dow Jones Indices use GICS: 11 sectors split into 25 industry groups, 74 industries and 163 sub-industries. SEC filings carry a four-digit SIC code. The two can place one company differently, because each looks at the business from its own angle.
Cite this page
Funkfolio, “Largest health care pharmaceutical companies by revenue”, data as of 20 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?sector=health-care&by=revenue
Underlying data: Yahoo Finance; SEC EDGAR.